What are the indications, dosing regimen, contraindications, and monitoring recommendations for dupilumab?

Dupilumab: Clinical Overview

Dupilumab is the preferred first-line systemic agent for moderate-to-severe atopic dermatitis in adults, with FDA approval for multiple indications including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, and bullous pemphigoid. 1, 2

FDA-Approved Indications

Dupilumab is FDA-approved for the following conditions 2:

• Atopic Dermatitis (adults and pediatric patients ≥6 months)
• Asthma (adults and pediatric patients ≥6 years)
• Chronic Rhinosinusitis with Nasal Polyps (adults and pediatric patients ≥12 years)
• Eosinophilic Esophagitis (adults and pediatric patients ≥1 year weighing ≥15 kg)
• Prurigo Nodularis (adults)
• Chronic Obstructive Pulmonary Disease (adults)
• Chronic Spontaneous Urticaria (adults and pediatric patients 12-17 years)
• Bullous Pemphigoid (adults)

Dosing Regimens

Atopic Dermatitis

Adults: 600 mg loading dose (two 300 mg injections) subcutaneously, followed by 300 mg every 2 weeks 2

Pediatric patients 6 years and older: 2

• 15 to <30 kg: 600 mg loading dose, then 300 mg every 4 weeks
• 30 to <60 kg: 400 mg loading dose (two 200 mg injections), then 200 mg every 2 weeks
• ≥60 kg: 600 mg loading dose, then 300 mg every 2 weeks

Pediatric patients 6 months to 5 years: 2

• 5 to <15 kg: 200 mg every 4 weeks (no loading dose)
• 15 to <30 kg: 300 mg every 4 weeks (no loading dose)

Asthma

Adults and pediatric patients ≥12 years: 2

• Standard: 400 mg loading dose (two 200 mg injections), then 200 mg every 2 weeks
• Alternative: 600 mg loading dose, then 300 mg every 2 weeks
• For oral corticosteroid-dependent asthma or co-morbid moderate-to-severe atopic dermatitis or chronic rhinosinusitis with nasal polyps: 600 mg loading dose, then 300 mg every 2 weeks

Pediatric patients 6-11 years: 2

• 15 to <30 kg: 300 mg every 4 weeks
• ≥30 kg: 200 mg every 2 weeks
• With co-morbid moderate-to-severe atopic dermatitis: Follow atopic dermatitis dosing with loading dose

Chronic Rhinosinusitis with Nasal Polyps

Adults and pediatric patients ≥12 years: 300 mg every 2 weeks (no loading dose specified) 2

Eosinophilic Esophagitis

Adults and pediatric patients ≥1 year weighing ≥15 kg: 2

• 15 to <30 kg: 200 mg every 2 weeks
• 30 to <40 kg: 300 mg every 2 weeks
• ≥40 kg: 300 mg every week

Prurigo Nodularis

Adults: 600 mg loading dose, then 300 mg every 2 weeks 2

Chronic Obstructive Pulmonary Disease

Adults: 300 mg every 2 weeks (no loading dose specified) 2

Chronic Spontaneous Urticaria

Adults: 600 mg loading dose, then 300 mg every 2 weeks 2

Pediatric patients 12-17 years: 2

• 30 to <60 kg: 400 mg loading dose, then 200 mg every 2 weeks
• ≥60 kg: 600 mg loading dose, then 300 mg every 2 weeks

Bullous Pemphigoid

Adults: 600 mg loading dose, then 300 mg every 2 weeks, used in combination with a tapering course of oral corticosteroids 2

Administration Details

• Route: Subcutaneous injection 2
• Preparation: Remove from refrigerator and allow to reach room temperature (45 minutes for 300 mg/2 mL; 30 minutes for 200 mg/1.14 mL) without removing needle cap 2
• Storage: Refrigerate at 36-46°F (2-8°C); once removed from refrigerator, must be used within 14 days or discarded 2
• Injection sites: Thigh, outer upper arm, or abdomen (except 2 inches around navel); rotate sites with each injection 2

Contraindications

The only absolute contraindication is known hypersensitivity to dupilumab or any excipients in the formulation. 2

Warnings and Precautions

Hypersensitivity Reactions

• Anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness, angioedema, urticaria, rash, erythema nodosum, and erythema multiforme have been reported 2
• If clinically significant hypersensitivity occurs, discontinue dupilumab immediately 2

Conjunctivitis and Keratitis

• Conjunctivitis occurred more frequently in atopic dermatitis patients receiving dupilumab compared to placebo 2
• Most patients recovered or were recovering during treatment 2
• Advise patients to report new onset or worsening eye symptoms; consider ophthalmological examination for persistent conjunctivitis or signs of keratitis 2
• In bullous pemphigoid trials, conjunctivitis occurred in 7.5% and keratitis in 3.8% of dupilumab-treated patients versus 0% in placebo 2

Eosinophilic Conditions

• Patients with asthma may present with eosinophilic pneumonia or eosinophilic granulomatosis with polyangiitis (EGPA), especially with oral corticosteroid reduction 2
• Monitor for vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury, and neuropathy in patients with eosinophilia 2

Corticosteroid Reduction

• Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiating dupilumab; taper gradually if appropriate 2
• For bullous pemphigoid, once disease control occurs, gradually taper corticosteroids and continue dupilumab as monotherapy 2

Psoriasis and Psoriatic Arthritis

• New-onset psoriasis symptoms have been reported 2
• Advise patients to report new joint or skin symptoms; consider dermatologic/rheumatologic evaluation and/or discontinuation if symptoms persist or worsen 2

Parasitic Infections

• Treat pre-existing helminth infections before initiating dupilumab 2
• If patients become infected during treatment and do not respond to anti-helminth therapy, discontinue dupilumab until infection resolves 2

Vaccinations

• Avoid use of live vaccines during dupilumab treatment 2

Monitoring Recommendations

While the FDA label does not specify routine laboratory monitoring, clinical monitoring should include 2:

• Baseline assessment: Evaluate for helminth infections in endemic areas
• Ongoing monitoring:
  • Eye symptoms (conjunctivitis, keratitis, visual disturbances)
  • Signs of hypersensitivity reactions
  • Eosinophil counts in asthma patients (for eosinophilic conditions)
  • Pulmonary, cardiac, renal, and neurologic symptoms in patients with eosinophilia
  • New-onset psoriasis or joint symptoms
  • Disease activity assessment using validated measures (EASI for atopic dermatitis, IGA scores)

Safety Profile

Dupilumab has an excellent safety track record with few major emergent safety concerns after more than 5 years in clinical practice. 1

Common Adverse Events (≥1-2% incidence depending on indication) 2:

• Injection site reactions
• Conjunctivitis
• Nasopharyngitis
• Upper respiratory tract infections
• Oral herpes and other herpes simplex virus infections
• Blepharitis, keratitis, eye pruritus, dry eye
• Eosinophilia
• Oropharyngeal pain
• Arthralgia
• Headache

Long-Term Safety

• A 5-year open-label extension study in adults with moderate-to-severe atopic dermatitis demonstrated sustained safety with exposure-adjusted rates of adverse events generally stable or declining throughout the study 3
• At week 260,67.5% achieved clear or almost clear skin (IGA 0/1) and 88.9% achieved ≥75% improvement in EASI 3

Clinical Positioning

Atopic Dermatitis

All guideline workgroup members surveyed favored dupilumab as the first-line systemic agent for moderate-to-severe atopic dermatitis. 1

• Dupilumab is somewhat less efficacious than higher doses of JAK inhibitors but has comparable efficacy to upadacitinib 15 mg daily and better efficacy than abrocitinib 100 mg daily 1
• Standard dosing is 600 mg loading dose, then 300 mg every 2 weeks 1
• Topical agents can be used concurrently for maintenance, rescue, or treatment of flares 1
• Consider phototherapy and/or systemic agents when topical therapy and basic management are optimized but inadequate 1

Dose Interval Extension

• The approved regimen of 300 mg every 2 weeks is recommended for long-term treatment 4
• Extended dosing intervals (every 4 or 8 weeks) resulted in dose-dependent worsening of response compared to weekly or every 2 weeks dosing 4
• A meta-analysis found extended dosing intervals (3-weekly or 4-weekly) were at least as effective as standard dosing in well-controlled patients, though this contradicts the pivotal trial data 5
• For optimal maintenance of response, continue the approved every 2 weeks regimen rather than extending intervals 4

Eosinophilic Esophagitis

• Symptomatic improvement requires higher systemic dupilumab exposure than histologic response 6
• The 300 mg weekly regimen approved for adults and adolescents ≥40 kg is supported by dose- and exposure-response relationships 6
• Patients with the highest exposures achieved greater symptomatic benefit, independent of strictures or history of dilation 6

Missed Doses 2

• Weekly dosing: Administer as soon as possible and start new weekly schedule from that date
• Every 2 weeks dosing:
  • If administered within 7 days of missed dose, resume original schedule
  • If not administered within 7 days, start new schedule from administration date
• Every 4 weeks dosing:
  • If administered within 7 days of missed dose, resume original schedule
  • If not administered within 7 days, start new schedule from administration date